Tepha, Inc., a Lexington, MA-based developer of medical devices derived from a new class of resorbable polymers that have been engineered utilizing recombinant DNA technology, has received a $3.2m credit facility from GE Capital, Healthcare Financial Services. The financing provides the company with working capital as it expands global commercialization efforts.
Tepha received its first FDA 510(k) clearance for its TephaFLEX® Absorbable Suture in February, 2007. The company and its partners have recently received five 510(k) clearances covering a range of medical devices including sutures, meshes, and films.
FinSMEs
16/07/2010